THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS

THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS

Pokaż inne wersje (1)

Opis bibliograficzny
Główni autorzy:	Monti, S, Leong, A, Robson, J, Craven, A, Merkel, P, Watts, R, Luqmani, R
Format:	Conference item
Wydane:	Oxford University Press 2017

Podobne zapisy

The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

FRI0312 The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

The association of vascular risk factors with visual loss in giant cell arteritis
od: Yates, M, i wsp.
Wydane: (2016)

O08 Blindness in patients with giant cell arteritis and its association with vascular disease
od: Yates, M, i wsp.
Wydane: (2016)

SY4_1 Giant cell arteritis (GCA) and Takayasu arteritis (TAK): a spectrum within the same disease or not? A report from the DCVAS project
od: Luqmani, R, i wsp.
Wydane: (2017)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

Updates on the diagnosis and monitoring of giant cell arteritis
od: Sara Monti, i wsp.
Wydane: (2023-02-01)

Giant cell arteritis: Current treatment and management
od: Ponte, C, i wsp.
Wydane: (2015)

The role of ultrasound in the management of giant cell arteritis in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS
od: Robson, J, i wsp.
Wydane: (2013)

THU0297 A novel ultrasound scoring system for giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis
od: Luqmani, R, i wsp.
Wydane: (2017)

Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?
od: Luqmani, R
Wydane: (2007)

P1_41 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the TABUL study (Temporal Artery Biopsy vs Ultrasound in diagnosis of Giant Cell Arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

Tumor necrosis factor-blocking agents in polymyalgia rheumatica and giant cell arteritis - Reply
od: Luqmani, R
Wydane: (2008)

THU0296 The role of ultrasound in the management of giant cell arteritis (GCA) in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

Giant Cell Arteritis
od: E. V. Shevchenko, i wsp.
Wydane: (2025-01-01)

The use of ultrasound to assess giant cell arteritis: Review of the current evidence and practical guide for the rheumatologist
od: Monti, S, i wsp.
Wydane: (2017)

ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS?
od: Soni, A, i wsp.
Wydane: (2009)

The role of a standardised ultrasound protocol in the management of giant cell arteritis (GCA) in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

European Headache Federation recommendations for neurologists managing giant cell arteritis
od: S. P. Mollan, i wsp.
Wydane: (2020-03-01)

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK
od: Robson, J, i wsp.
Wydane: (2013)

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.
od: Robson, J, i wsp.
Wydane: (2015)

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK
od: Robson, J, i wsp.
Wydane: (2015)

Giant cell arteritis: new concepts, treatments and the unmet need that remains
od: Coath, F, i wsp.
Wydane: (2018)

Scalp Necrosis Revealing Severe Giant-Cell Arteritis
od: Safa Idoudi, i wsp.
Wydane: (2020-01-01)

Giant cell arteritis
od: Dijana Perković, i wsp.
Wydane: (2021-04-01)

Giant Cell Arteritis
od: Bruno Coulier, i wsp.
Wydane: (2018-01-01)

Vascular Endothelial Growth Factor as an Aid to Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

Methotrexate (MTX) failed to control giant cell arteritis (GCA)
od: Hoffman, G, i wsp.
Wydane: (2001)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
od: Goodfellow, N, i wsp.
Wydane: (2017)

Biologic Therapies for Giant Cell Arteritis
od: Harrington R, i wsp.
Wydane: (2021-01-01)

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study
od: Robson, J, i wsp.
Wydane: (2016)

FRI0028 Vascular Endothelial Growth Factor as An Aid To Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

Giant‐cell arteritis with toothache
od: Jun Usami
Wydane: (2024-05-01)

Giant Cell Arteritis of the Breast
od: Nur BÜYÜKPINARBAŞILI, i wsp.
Wydane: (2015-12-01)

Giant femoral aneurysm in giant cell arteritis
od: Muhammed Bayram, i wsp.
Wydane: (2022-01-01)